MARKET

RXRX

RXRX

Recursion Pharmaceuticals, Inc.
NASDAQ
4.820
+0.110
+2.34%
After Hours: 4.830 +0.01 +0.20% 18:03 12/08 EST
OPEN
4.975
PREV CLOSE
4.710
HIGH
5.09
LOW
4.680
VOLUME
34.85M
TURNOVER
--
52 WEEK HIGH
12.36
52 WEEK LOW
3.790
MARKET CAP
2.51B
P/E (TTM)
-2.6640
1D
5D
1M
3M
1Y
5Y
1D
Why Recursion Pharamaceuticals Topped the Market Today
The Motley Fool · 4h ago
Recursion rises on new data for asset for polyps
Seeking Alpha · 7h ago
BUZZ-U.S. STOCKS ON THE MOVE-Five Below, Boeing, Instacart
Reuters · 7h ago
Promising Clinical Study Results and FDA Meeting Propel Buy Rating for Recursion Pharmaceuticals
TipRanks · 9h ago
Why Are Shares Of Recursion Pharmaceuticals Higher Today?
Benzinga · 10h ago
Unusually active option classes on open December 8th
TipRanks · 12h ago
BUZZ-U.S. STOCKS ON THE MOVE-Micron, NextEra Energy, Ocular Therapeutix
Reuters · 12h ago
RECURSION PHARMACEUTICALS SHARES UP 6.1% AFTER CO'S EXPERIMENTAL THERAPY REDUCES POLYP GROWTH IN RARE DISEASE TRIAL
Reuters · 12h ago
More
About RXRX
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.

Webull offers Recursion Pharmaceuticals Inc stock information, including NASDAQ: RXRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RXRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RXRX stock methods without spending real money on the virtual paper trading platform.